Global Skin Cancer Therapeutics Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4388555
  • Report
  • Region: Global
  • 211 Pages
  • Mordor Intelligence
1 of 5
The Global Skin Cancer Therapeutics Market Was Valued at USD 12.79 Billion in 2016

FEATURED COMPANIES

  • Aqua Pharmaceuticals LLC
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Elekta AB
  • Eli Lilly and Co.
  • F. Hoffmann-la Roche Ltd
  • MORE

Skin cancer is the uncontrolled growth of abnormal skin cells. It occurs when unrepaired DNA damage to skin cells (most often caused by ultraviolet radiation from sunshine or tanning beds) triggers mutations, or genetic defects, that lead the skin cells to multiply rapidly and form malignant tumors.

As per the WHO, the incidence of both, non-melanoma and melanoma skin cancers, has been increasing over the past decade, with around 2 to 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occurring, globally, every year. Since 2011, eight new drugs have been FDA approved for the treatment of melanoma, including four immunotherapies and four targeted therapies. With over 50 drugs in the pipeline and major players like Roche, Merck, BMS, Novartis and Eisai investing heavily into R&D, the market for skin cancer treatment shows assured promise in the coming years.

Drivers

Increasing incidence of skin cancer, extensive R&D pipelines, increasing usage of combination therapies are some of the factors which are expected to drive the demand for skin cancer therapeutics over the forecast period.

Restraints

Side-effects and complications associated with radiation therapy, stringent regulatory guidelines have been observed to restrain the overall growth of the market.

Market Segmentation

This market is segmented, on the basis of product, into bone growth stimulation devices, bone morphogenetic proteins, and platelet-rich plasma. The market is also segmented, on the basis of application, into spinal fusion surgeries, delayed union & nonunion bone fractures, oral and maxillofacial surgeries, and others. The market is further segmented, on the basis of end user, into hospitals & clinics, home care and academic & research institutes, and CROs. Based on geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. These regions are further segmented by their respective countries.

Report Structure

Global Skin Cancer Therapeutics Market into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. These regions are further segmented by their respective countries.

Some of the Key Players in this Market include:

  • F. Hoffmann-la Roche Ltd
  • Valeant Pharmaceuticals Inc.
  • Novartis International AG
  • Pfizer
  • Elekta AB
  • Varian Medical Systems Inc.
  • Meda AB
  • iCAD Inc.
  • Merck & Co. Inc.
  • Eli Lilly and Co.
  • Bristol Myers Squibb Co.
  • Boehringer Ingelheim GmbH
  • Aqua Pharmaceuticals LLC

Over the past three years, these players have adopted product launches & enhancements, strategic acquisitions, and market expansions as their core business strategies to ensure dominance in this market.

Key Deliverables:

  • Market analysis of the Global Skin Cancer Therapeutics market with region-specific assessments and competition analysis
  • Market definition, along with the identification of key drivers, restraints opportunities, and challenges
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale
  • Extensively researched competitive landscape section with company profiles of key players, along with the analysis of their current strategic interests and key financial information
  • Identification and analysis of the macro and micro factors that affect the Global Skin Cancer Therapeutics market
  • Insights of the market in the regions that have the highest potential for growth and identify the markets that are still untapped
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aqua Pharmaceuticals LLC
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Elekta AB
  • Eli Lilly and Co.
  • F. Hoffmann-la Roche Ltd
  • MORE

1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Degree of Competition
5.2.4 Threat of Substitution
5.2.5 Threat of New Entrants

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence of Skin Cancer
6.1.2 Extensive R&D Pipelines
6.1.3 Increasing Usage of Combination Therapies
6.2 Market Restraints
6.2.1 Side Effects and Complications Associated With Radiation Therapy
6.2.2 Stringent Regulatory Guidelines
6.3 Market Opportunities
6.4 Key Challenges

7. Global Skin Cancer Market Segmentation
7.1 by Type
7.1.1 Melanoma
7.1.1.1 Systemic Immunotherapies
7.1.1.1.1 Checkpoint Inhibitors
7.1.1.1.1.1 Yervoy
7.1.1.1.1.2 Keytruda
7.1.1.1.1.3 Opdivo
7.1.1.1.2 Oncolytic Virus Therapy
7.1.1.1.2.1 T-Vec, Lymgic
7.1.1.2 Targeted Therapies
7.1.1.2.1 Zelboraf
7.1.1.2.2 Tafinlar
7.1.1.2.3 Mekinist
7.1.1.2.4 Cotellic
7.1.2 Non-Melanoma
7.1.2.1 by Type
7.1.2.1.1 Basal Cell Carcinoma
7.1.2.1.2 Squamous Cell Carcinoma
7.1.2.2 by Treatment Method
7.1.2.2.1 Non-Invasive Treatment
7.1.2.2.1.1 Laser Therapy
7.1.2.2.1.2 Radiotherapy
7.1.2.2.1.3 Photodynamic Therapy (PDT)
7.1.2.2.1.4 Cryotherapy
7.1.2.2.1.5 Others
7.1.2.2.2 Chemotherapy Treatment
7.1.2.2.2.1 Systemic Chemotherapy
7.1.2.2.2.1.1 Cisplatin
7.1.2.2.2.1.2 Doxorubicin
7.1.2.2.2.1.3 5-Fluorouracil
7.1.2.2.2.1.4 Capecitabine
7.1.2.2.2.1.5 Topotecan
7.1.2.2.2.1.6 Etoposide
7.1.2.2.2.2 Targeted Chemotherapy
7.1.2.2.2.2.1 Erivedge
7.1.2.2.2.2.2 Odomzo
7.1.2.2.2.2.3 Odomzo
7.2 by Geography
7.2.1 North America
7.2.1.1 USA
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia & New Zealand
7.2.3.5 South Korea
7.2.3.6 Rest of Asia-Pacific
7.2.4 Middle East and Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of Middle East and Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers and Acquisitions Analysis
8.2 New Product Launches
8.3 Agreements, Collaborations & Partnerships

9. Company Profiles
9.1 F.Hoffmann-La Roche Ltd.
9.2 Valeant Pharmaceuticals Inc.
9.3 Novartis International AG
9.4 Elekta AB
9.5 Varian Medical Systems Inc.
9.6 Meda AB
9.7 ICAD Inc.
9.8 Merck & Co. Inc.
9.9 Eli Lilly and Co.
9.10 Bristol Myers Squibb Co.
9.11 Boehringer Ingelheim Gmbh
9.12 Aqua Pharmaceuticals Llc
9.13 Others

10. Future Outlook of the Market

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aqua Pharmaceuticals LLC
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Elekta AB
  • Eli Lilly and Co.
  • F. Hoffmann-la Roche Ltd
  • iCAD Inc.
  • Meda AB
  • Merck & Co. Inc.
  • Novartis International AG
  • Pfizer
  • Valeant Pharmaceuticals Inc.
  • Varian Medical Systems Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll